AC
HZNP

Athanor Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Athanor Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,934
Closed -$270K – 1035
2021
Q1 		$270K Sell
2,934
-458
-14% -$38.6K 0.01% 615
2020
Q4 		$248K Buy
+3,392
New +$252K 0.01% 611

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Athanor Capital's HZNP Position: Q2 2021 in Review

Athanor Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2021, closing a stake of 2,934 shares — an estimated $270K sold.

Athanor Capital first reported a position in HZNP in Q4 2020 and held it in 2 quarters. The position peaked at $270K in Q1 2021. 526 funds tracked by Wall St. Rank hold HZNP as of Q2 2021.

  • Athanor Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 2,934 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2021, an estimated $270K.
  • Athanor Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 2 quarters.
  • Athanor Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $270K in Q1 2021.
  • 526 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.